0001610717-24-000364.txt : 20240626 0001610717-24-000364.hdr.sgml : 20240626 20240626162621 ACCESSION NUMBER: 0001610717-24-000364 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240624 FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelsey Stephen Michael CENTRAL INDEX KEY: 0001462808 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 241073747 MAIL ADDRESS: STREET 1: C/O GERON CORPORATION STREET 2: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 form4.xml X0508 4 2024-06-24 0001628171 Revolution Medicines, Inc. RVMD 0001462808 Kelsey Stephen Michael C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 true See Remarks true Common Stock 2024-06-24 4 M 0 200 4.09 A 269273 D Common Stock 2024-06-24 4 S 0 200 39 D 269073 D Common Stock 2024-06-25 4 M 0 16467 4.09 A 285540 D Common Stock 2024-06-25 4 S 0 16467 39.057 D 269073 D Stock Option (Right to Buy) 4.09 2024-06-24 4 M 0 200 0 D 2023-03-13 2029-03-12 Common Stock 200 106466 D Stock Option (Right to Buy) 4.09 2024-06-25 4 M 0 16467 0 D 2023-03-13 2029-03-12 Common Stock 16467 89999 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Includes 95,476 restricted stock units. The transaction was executed in multiple trades in prices ranging from $39.00 to $39.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. President, Research and Development /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey 2024-06-26